Press release summary
Precure has selected Helix to provide laboratory services and artificial intelligence tools for a planned population-scale multi-omics program involving about 1 million biospecimens. Precure, launched by Mayo Clinic with Thermo Fisher Scientific, aims to combine molecular measurements with de-identified longitudinal clinical information to study biological changes that precede disease symptoms.
Helix said its role will include clinical whole-genome sequencing, research-grade proteome sequencing, workflow orchestration, data infrastructure and AI tools. The company plans to use a fleet of Ultima Genomics UG 200 sequencing systems to produce genomic data and proteomic readouts. Helix also cited its CLIA- and CAP-regulated sequencing capabilities.
Why it matters for laboratories
The announcement adds critical operational detail to Precure’s broader research plan by identifying the laboratory, data and sequencing infrastructure expected to support it. At the proposed scale, the program could test how clinical-grade genomics and research proteomics are coordinated across sample processing, data governance and health-system workflows. The release does not disclose a timetable, contract value or detailed validation plan, and the anticipated clinical and research benefits remain prospective.
Original source: Helix release distributed through PR Newswire, Sept. 21, 2026.
